High-dose therapy with stem cell rescue

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.

Original languageEnglish (US)
Title of host publicationThe Lymphoid Neoplasms 3ed
PublisherCRC Press
Pages954-969
Number of pages16
ISBN (Electronic)9781444113228
ISBN (Print)9780340809471
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'High-dose therapy with stem cell rescue'. Together they form a unique fingerprint.

Cite this